Wardynski & Partners has advised Genomtec on the transfer of its listing from NewConnect to the main market of the Warsaw Stock Exchange.
"Genomtec is the 418th company to be listed on the main market of the WSE and the fourth debut on the main market in 2023," Wardynski & Partners informed. "At the opening of the first trading session, the company’s shares rose more than 2%, to PLN 14.20."
Founded in 2016, Genomtec is a medical technology company in Wroclaw. The company conducts research and development on the application of isothermal methods in molecular diagnostics.
The Wardynski & Partners team included Partner Marcin Pietkiewicz and Attorney-at-Law Katarzyna Jaroszynska.
